Trial Profile
Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Durvalumab (Primary) ; Ramucirumab (Primary) ; Rucaparib (Primary) ; Trastuzumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms PLATFORM
- 20 Jan 2024 Results(n=24) presented at the 2024 Gastrointestinal Cancers Symposium
- 24 Oct 2023 Interim results (at data cut-off 28 April 2023, n=125) presented at the 48th European Society for Medical Oncology Congress.
- 11 May 2023 Planned End Date changed from 1 Jun 2025 to 1 Jun 2027.